Cardiff Oncology to participate in investor meetings at Piper Sandler Healthcare Conference, showcasing PLK1 inhibition therapies.
Quiver AI Summary
Cardiff Oncology, Inc. has announced that its management will participate in a fireside chat and one-on-one investor meetings at the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025. CEO Mark Erlander, PhD, will present on December 2 at 9:30 AM ET. Participants can access the live webcast through the Cardiff Oncology website, which will have a replay available afterward. Cardiff Oncology is focused on developing new cancer therapies using PLK1 inhibition, with its lead drug, onvansertib, currently in trials for various types of cancer, including metastatic colorectal cancer and small cell lung cancer, among others. The company's approach aims to exploit tumor vulnerabilities to improve treatment outcomes compared to standard therapies.
Potential Positives
- Participation in the Piper Sandler 37th Annual Healthcare Conference enhances visibility and credibility for Cardiff Oncology among investors and industry leaders.
- Live webcast of the fireside chat allows for broader public access to the company's insights and developments, potentially attracting more interest and investment.
- Highlighting ongoing clinical programs for innovative therapies positions Cardiff Oncology as a key player in the oncology sector, particularly with its focus on overcoming treatment resistance.
- Engagement from top management, such as the CEO, signifies a commitment to transparency and investor relations, which can strengthen stakeholder trust and support.
Potential Negatives
- None
FAQ
What is Cardiff Oncology participating in at the Piper Sandler Healthcare Conference?
Cardiff Oncology will participate in a fireside chat and 1x1 investor meetings at the conference from December 2-4, 2025.
Who will present for Cardiff Oncology during the event?
Mark Erlander, PhD, the CEO of Cardiff Oncology, will be presenting at the conference.
What time is Cardiff Oncology's presentation scheduled for?
The presentation is scheduled for December 2, 2025, at 9:30 AM ET.
How can interested parties access the conference webcast?
Interested parties can register and access the live webcast in the "Events" section of the Cardiff Oncology website.
What is the focus of Cardiff Oncology's drug development?
Cardiff Oncology focuses on PLK1 inhibition to develop therapies for various cancers, including colorectal and pancreatic cancers.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CRDF Insider Trading Activity
$CRDF insiders have traded $CRDF stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CRDF stock by insiders over the last 6 months:
- GARY W PACE has made 2 purchases buying 290,000 shares for an estimated $710,500 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CRDF Hedge Fund Activity
We have seen 50 institutional investors add shares of $CRDF stock to their portfolio, and 64 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,423,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,931,380
- MILLENNIUM MANAGEMENT LLC removed 1,090,769 shares (-96.8%) from their portfolio in Q3 2025, for an estimated $2,246,984
- LAURION CAPITAL MANAGEMENT LP added 668,590 shares (+37.2%) to their portfolio in Q3 2025, for an estimated $1,377,295
- ORBIMED ADVISORS LLC removed 573,884 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,807,734
- ACORN CAPITAL ADVISORS, LLC added 553,317 shares (+39.3%) to their portfolio in Q3 2025, for an estimated $1,139,833
- FLPUTNAM INVESTMENT MANAGEMENT CO added 543,370 shares (+1008.8%) to their portfolio in Q3 2025, for an estimated $1,119,342
- MORGAN STANLEY removed 485,087 shares (-61.0%) from their portfolio in Q3 2025, for an estimated $999,279
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CRDF Analyst Ratings
Wall Street analysts have issued reports on $CRDF in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Ladenburg Thalmann issued a "Buy" rating on 07/08/2025
To track analyst ratings and price targets for $CRDF, check out Quiver Quantitative's $CRDF forecast page.
$CRDF Price Targets
Multiple analysts have issued price targets for $CRDF recently. We have seen 3 analysts offer price targets for $CRDF in the last 6 months, with a median target of $10.0.
Here are some recent targets:
- Robert Burns from HC Wainwright & Co. set a target price of $10.0 on 08/06/2025
- Kevin DeGeeter from Ladenburg Thalmann set a target price of $19.0 on 07/08/2025
- Maury Raycroft from Jefferies set a target price of $3.5 on 06/24/2025
Full Release
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Piper Sandler 37 th Annual Healthcare Conference, which is taking place from December 2-4, 2025.
Details of the presentation can be found below.
Presenters:
Mark Erlander, PhD (CEO)
Date:
12/02/2025
Time:
9:30 AM ET
Interested parties can register for and access the live webcast for the conferences by visiting the “ Events ” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit
https://www.cardiffoncology.com
.
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
[email protected]
Investor Contact:
Candice Masse
Astr Partners
[email protected]
Media Contact:
Amy Bonanno
Lyra Strategic Advisory
[email protected]
